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Molecular profiling of tumors promises to advance the clinical management of cancer, but the
benefits of integrating molecular data with traditional clinical variables have not been
systematically studied. Here we retrospectively predict patient survival using diverse molecular
data (somatic copy-number alteration, DNA methylation and mRNA, miRNA and protein
expression) from 953 samples of four cancer types from The Cancer Genome Atlas project. We
found that incorporating molecular data with clinical variables yielded statistically significantly
improved predictions (FDR < 0.05) for three cancers but those quantitative gains were limited
(2.2–23.9%). Additional analyses revealed little predictive power across tumor types except for
one case. In clinically relevant genes, we identified 10,281 somatic alterations across 12 cancer
types in 2,928 of 3,277 patients (89.4%), many of which would not be revealed in single-tumor
analyses. Our study provides a starting point and resources, including an open-access model
evaluation platform, for building reliable prognostic and therapeutic strategies that incorporate
molecular data.
Introduction
The Cancer Genome Atlas (TCGA) project has yielded many biological insights through
generating genomic, transcriptomic, epigenomic and proteomic data from a large number of
patient samples in many cancer types1–6. However, the potential clinical utility of these data
in aggregate remains largely unknown.
Large-scale molecular profiling data may be informative for multiple aspects of oncology
practice. One key application for patients with primary disease is accurate prognosis, which
helps stratify patients into different risk groups and choose both treatment and surveillance
strategies. Traditionally, prognosis is based on clinical variables such as age and tumor
stage. Recently, extensive efforts have been made to incorporate molecular information for
better prognosis. For example, ER, PR and HER2 protein levels and HER2 genomic
amplification are important biomarkers in breast cancer that have demonstrated high value
in clinical use7. However, owing to the high cost of molecular profiling on a large scale,
previous studies have either focused on a small number of selected genes or have employed
only single-platform genomic data (e.g., microarrays). By convention, such studies have
been limited to a single cancer lineage. Another important clinical application is to choose
targeted therapies based on the alteration spectrum in an individual patient’s tumor. Multiple
efforts have been initiated to apply high-throughput sequencing data in clinical strategies,8, 9
although alterations in clinically actionable genes have not been fully cataloged. Knowledge
of this catalog may inform target selection for drug development as well as clinical trial
design and identify patient populations that may benefit from emerging targeted
therapeutics.
The overall goal of this study was to address how and to what extent TCGA molecular data
could impact oncology practice. Thus, we evaluated two closely related but distinct aspects
of clinical utility—prognostic utility (that is, predicting patient survival using various types
of high-throughput molecular data across multiple tumor lineages) and therapeutic utility
(that is, identifying the spectrum of somatic alterations in clinically actionable genes, which
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tin the future may inform treatment selection). First, we examined the performance of
molecular data (somatic copy number alteration (SCNA), DNA methylation and mRNA,
microRNA and protein expression) alone or in combination with clinical variables in
predicting censored or dichotomized patient survival data for four TCGA cancer types with
high-quality overall survival data. Furthermore, to facilitate a broader community effort, we
developed an open-access platform that allows researchers to build and evaluate survival
prediction models on these datasets. Here we did not intend to generate prognostic models
ready for clinical use, but rather we sought to provide insights into how to improve such
models by incorporating informative molecular data. Second, we investigated the current
spectrum of potentially clinically actionable alterations (somatic point mutations and small
insertions/deletions) across 12 TCGA tumor types. By analyzing molecular data from
multiple cancer types, we were able to evaluate prognostic models and identify alterations
that would not have been obtained with single-tumor datasets.
Results
Assessment of prognostic power of diverse molecular data
We focused on four TCGA cancer types: kidney renal clear cell carcinoma (KIRC)6,
glioblastoma multiforme (GBM)1, ovarian serous cystadenocarcinoma (OV)2 and lung
squamous cell carcinoma (LUSC)4. These cancer types were chosen because their TCGA
datasets included survival data with adequate follow-up time and sufficient samples
characterized by multiple types of molecular data. The TCGA cohorts have overall survival
patterns similar to those reported in previous publications10–13. For each cancer type, we
compiled a core sample set in which each sample has information available for the overall
survival time, clinical variables (e.g., gender, age, tumor stage and grade) and at least four
out of the five types of molecular data related to gene expression (SCNA: Affymetrix
Human SNP Array 6.0, ~100 arm or focal alterations; DNA methylation: Illumina DNA
Methylation microarray, ~20,000 genes; mRNA expression: Agilent 244K microarray or
Illumina mRNA-seq, ~20,000 genes; miRNA expression: Agilent Human miRNA-specific
microarray or Illumina miRNA-seq, >500 microRNAs; protein expression: Reverse Phase
Protein Array, ~170 proteins) (Table 1).
For each core sample set, we applied an approach of Monte Carlo cross-validation and
assessed the predictive power of individual molecular data types or clinical variables using
the concordance index (C-index)14. The C-index is a non-parametric measure to quantify the
discriminatory power of a predictive model: C-index = 1 indicates perfect prediction
accuracy and C-index = 0.5 is as good as a random guess (Online Methods). We compiled
candidate features from molecular data or clinical data for each cancer type and randomly
split the core set into training and test sets 100 times (Fig. 1a). We built the predictive
models from the training set using two well-established, but highly complementary methods:
(i) Cox, the multivariate Cox proportional hazards model with L1 penalized log partial
likelihood (LASSO)15 for feature selection, and (ii) random survival forest (RSF)16.
For each cancer type, the clinical-variable-only models showed substantial predictive power,
with C-indexes significantly higher than 0.5 (range: 0.624–0.754; P = 0) (Fig. 1b–e and
Supplementary Figure 1). In 9 out of 18 cases, the models built from individual molecular
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tdata sets alone showed statistically significant predictive power (Supplementary Figure 1),
but in only one case, the model built from LUSC protein expression data had predictive
power similar to that of the corresponding clinical-variable-only model (Fig. 1e, C-index
0.632 vs. 0.626, P = 0.40, Wilcoxon signed rank test). The relative predictive power of
individual molecular datasets strongly depended on the cancer type: for example, the
prognostic power was much higher for KIRC than for the other three cancer types. In
general, the trends observed with the Cox models were similar to those observed using the
RSF models.
To examine whether genomic and proteomic data can provide additional prognostic power
when used with clinical variables, we built predictive models by integrating clinical
variables with each type of molecular data (both gene-level features and molecular subtype
features) (Online Methods). Notably, the integrated models resulted in statistically
significantly improved predictive power compared to those clinical-variable-only models in
three cancer types, including mRNA, microRNA and protein expression in KIRC, miRNA
expression in OV and protein expression in LUSC (one-sided Wilcoxon signed rank test,
KIRC clinical + mRNA: P < 3.3×10−3, FDR < 0.035; clinical + miRNA: P < 1.2×10−4, FDR
< 2.1×10−3; clinical + protein: P < 8.4×10−5, FDR < 2.1×10−3; OV clinical + miRNA: P <
7.0×10−5, FDR < 2.1×10−3; LUSC clinical + protein: P < 7.9×10−4, FDR < 0.011) (Fig. 1b–
e). However, in terms of quantitative gain (i.e., the median value of Somers’ D14 across the
100 splits, a measurement for C-index change), the increase was limited (KIRC clinical +
mRNA: 4.0%, clinical + miRNA: 7.4%, clinical + protein: 2.2%; OV clinical + miRNA:
13.7%; LUSC clinical + protein: 23.9%). In addition, we examined the effects of machine
learning algorithms, feature selection and sample size of the training set on model
performance (Supplementary text and Supplementary Figs 2–4).
To facilitate a broader community effort for such modeling, we developed an open-access
platform that allows researchers to evaluate and submit survival prediction models in a
“collaborative competition” research framework (Supplementary Fig. 5). The homepage of
the TCGA Pan-Cancer Survival Prediction challenge can be accessed in Synapse (doi:
10.7303/syn1710282). The site contains all models used in this study, including provenance
records and transparent source code that allows each model to be inspected, rerun, or
improved upon. Each model is linked to a standard set of meta-data annotations that provide
online querying capability (e.g., corresponding to the cancer type or learning algorithm),
allowing for the comparison of models based on user-defined criteria. The C-index scores
for each model, as reported here, are displayed in the form of a real-time leaderboard.
Biological insights from top-performing prognostic models
For the top prognostic models highlighted in Figure 1, we further examined important
molecular features included in each model to gain some mechanistic insights. The LUSC
protein expression model is the only case where the molecular data alone showed a
performance similar to that of the clinical-variable-only model. Features in the model with
high predictive ability16 were dominated by proteins involved in DNA repair and
microsatellite instability (e.g., MSH2) and metabolism (e.g., ACC1) (Supplementary Table
1).
Yuan et al. Page 4
Nat Biotechnol. Author manuscript; available in PMC 2015 January 01.
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
tAs shown in Figure 1, molecular data in five integrative models conferred additional
prognostic power given clinical variables. Notably, in four of these models, the only
contributing molecular feature was the molecular subtype derived from the corresponding
expression data (through consensus nonnegative matrix factorization (NMF)17). Molecular
subtypes can be regarded as higher-level assembles of individual gene features and therefore
may act as a more robust predictor than an individual marker or small marker sets. Indeed,
the NMF subtypes (derived from OV miRNA expression, LUSC protein expression and
KIRC mRNA and protein expression data, respectively) showed distinct survival patterns in
the respective cancer types(log-rank test, Fig. 2c, P < 0.043; Fig. 2e, P < 8.2×10−3;
Supplementary Fig. 6a, P < 9.8×10−5; Supplementary Fig. 7a, P < 1.1×10−4).
Given the limited availability of suitable independent data in the public domain, we
evaluated the performance of the OV clinical + miRNA model. Using the multiclass
classifier built from TCGA OV miRNA expression data (Fig. 2a, Online Methods, the area
under the receiver operating characteristic curve [AUC] = 0.98, Fig. 2b), we recovered the
survival pattern of the NMF subtypes observed for the TCGA core set (Fig. 2c, log-rank test
P < 0.043) in an independent cohort18 (Fig. 2d, log-rank test P < 6.3×10−3): the patients in
cluster 3 have better survival than those in clusters 1 and 2 (prognostic miRNAs in each
cluster are shown in Supplementary Table 2). Further, applying this trained model to the
independent cohort yielded the expected improvement for including the miRNA NMF
subtypes.
For the molecular subtypes defined by LUSC protein expression, pMEK1 and pMAPK and
the downstream target pS6 were among the top markers expressed at higher levels in
patients with shorter survival times (clusters 2 and 3, Fig. 2e,f). Clinical and preclinical data
suggest that MEK inhibitors are active in specific subsets of non-small cell lung cancer, such
as KRAS-mutated lung adenocarcinomas19, 20. Our results suggest that patients with high-
risk forms of LUSC have relatively greater activation of the RAS/MEK/MAPK pathway and
that MEK targeting warrants further exploration in this population as well. In addition, the
mTOR and Src pathways may also be more active in cluster 3, whereas DNA-repair protein
levels were low in both clusters 2 and 3 (Fig. 2f). Gene signatures associated with KIRC
mRNA expression subtypes were aligned with their reported biological roles and survival
patterns: many proteins involved in acute-phase response signaling and several pro-
metastatic matrix metalloproteases were highly expressed in the groups with worse survival
outcomes (clusters 2 and 3)21, 22, whereas death receptor signaling proteins were down-
regulated in these groups23 (Supplementary Fig. 6a,b). The survival pattern of the NMF
subtypes by KIRC protein expression also matches the survival correlations of individual
protein markers (Supplementary Fig. 7a,b).
Finally, the KIRC clinical + miRNA model was the only integrative model for which
individual gene features, instead of a molecular subtype derived from the complete
expression dataset, provided additional prognostic power. Each of the six miRNAs
comprising the signature was significantly correlated with survival, and their hazard ratio
matched with previously reported roles in cancer progression. Although up-regulation of
miR-21, which has growth promoting activity, is associated with a worse prognosis24, 25, the
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tremaining miRNAs (miR-192, miR-101, let-7a, let-7f and miR-143) suppress tumor growth,
with higher expression being associated with a better prognosis26–31 (Fig. 2g).
Patient survival prediction using cross-tumor models
To test whether molecular data could identify commonalities across different tumor types,
we assessed whether a model trained using molecular data in one cancer type could predict
survival in other cancer types that share the same type of molecular data generated by the
same platform (Online Methods). In the vast majority of cases, the C-index was around 0.5,
suggesting little predictive power across tumor types (Supplementary Fig. 8).
However, a model trained from OV SCNA data was predictive of survival for patients with
KIRC, with a median C-index of 0.67 (Fig. 3a, Supplementary Fig. 9). Furthermore, given
the same KIRC test sets, the OV model showed higher predictive power than a model
trained from SCNA data of the KIRC training samples (Fig. 3a, median C-index, 0.67 vs.
0.59, P = 4.7×10−9, Wilcoxon signed rank test). When we randomly sampled the same
number of OV samples as the KIRC training sets to build the predictive model, the C-index
dropped from 0.67 to 0.54, suggesting that the higher predictive power was largely due to
the larger sample size of the OV core set. We further confirmed this pattern using an
independent approach and an independent sample partition (Supplementary Fig. 10, Online
Methods). Closer examination revealed one common feature (“12q”) among the features
selected from SCNA of the whole OV core set and KIRC core set, which may be crucial for
the cross-tumor predictive power. In addition to 12q, there were another four arm-level
SNCA features included in the model trained from OV SCNA data: 12p, 16q, 20p and 20q,
all of which showed significant amplification of q-values in KIRC according to GISTIC232
(Fig. 3b). Indeed, the KIRC q-values of the features selected from OV SCNA data were
lower than those not selected (Fig. 3b, P = 1.6×10−3, Wilcoxon rank sum test). The shared
biological features identified above provide key insights into mechanistic connections
between the two cancer types.
Factors affecting prediction of dichotomized survival data
In addition to analysis on censored survival data, we examined the power of molecular data
in predicting dichotomized overall survival data. Unlike censored survival data, there are
many machine-learning algorithms for classifying binary clinical outcomes. Although the
process of dichotomization will lose some information, this practice enables us to
systematically survey many modeling scenarios and assess the effect of different factors on
predicting survival data. For each cancer type, we dichotomized the censored continuous
survival data through a designated cutoff time (survival milestone) (Online Methods), and
then constructed a series of models from individual molecular data alone or with clinical
variables by (i) using eight common classification algorithms, (ii) applying two feature pre-
selection strategies and (iii) including different numbers of final features in the model. In
total, we assessed the performance of >5,000 models through 10-fold cross-validation based
on the threshold-independent AUC score.
Figure 4a–d and Supplementary Table 3 show the AUC score for each algorithm, with the
optimal setting for each dataset and each cancer. Overall, as observed for continuous
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tsurvival data, the predictive power of molecular data strongly depended on the cancer type.
Clinical variables showed better performance than individual molecular data except for
LUSC, where the protein expression data showed better performance than the clinical
variables given the best-performing algorithms (Fig. 4d). Moreover, the integration of
molecular data with clinical variables improved the predictive power, especially for the
following datasets: DNA methylation and protein expression in KIRC using most algorithms
(Fig. 4a), mRNA expression in GBM using K-nearest neighbor (KNN), nearest centroid
(NC) and support vector machine (SVM) (Fig. 4b), and protein expression in OV and LUSC
using most algorithms (Fig. 4c,d). To quantify the effects of specific factors on survival
prediction, we performed an analysis of variance (ANOVA) on the AUC scores, and found
that cancer type, data type and their interactions were the three dominant sources of
variability, respectively explaining 35.7%, 17.4% and 11.8% of the variability of the
prediction performance (Fig. 4e, violet bars). In contrast, the effect of machine-learning
algorithms was moderate (5.2%). We obtained similar results when the sample size was kept
consistent across all cancer types (Fig. 4e, green bars, Online Methods). These results were
consistent with the recent microarray quality control (MAQC)-II study33.
Somatic alterations in clinically relevant genes
Finally, we assessed the therapeutic utility of TCGA data by analyzing somatic mutations
and small insertion/deletions (indels) in 3,277 patients across 12 tumor types. We applied a
heuristic algorithm34, 35 to score the clinical importance of each alteration in 121 clinically
relevant genes. Clinically relevant genes were defined as those that, when somatically
altered, may predict resistance or response to a therapy and/or have diagnostic or prognostic
relevance for a particular tumor type36 (Online Methods). It is important to emphasize that
not all aberrations in clinically relevant genes will act as “drivers” and portend response to
therapeutic targeting, and that a majority of the alterations in these clinically relevant genes
remain variants of uncertain clinical significance and require further experimental and
clinical evaluation.
In 89.4% (2,928/3,277) of the TCGA patient samples, 10,281 somatic non-synonymous
alterations (1.62% of all alterations, synonymous or non-synonymous, in this combined
cohort) in 121 clinically relevant cancer genes were observed (Fig. 5a,b). Of these, 1,287
alterations in 31.4% (1,028/3,277) of patients were observed in genomic hotspots that were
tested for in representative prospective clinical settings using a panel that probes events in
41 genes9. As expected, by extending genomic profiling to cover all exons of the same gene
set, we observed a large increase in the number of observed alterations in clinically relevant
genes in all 12 tumor types (Fig. 5c,d). This result reflects the gap in the understanding of
the clinical relevance of a majority of alterations in genes potentially linked to clinical
actions. To exclude the effect of hypermutated tumors in this cohort (e.g., colorectal,
endometrial)3, 5, we repeated the analysis for tumors with mutation rates of ≤ 10
mutations/Mb (n = 2,892) as suggested in previous TCGA studies. We observed 3.5%
(6,153/177,977) somatic alterations in the 121 clinically relevant genes (Supplementary
Figure 11).
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oncology. First, well-characterized clinically relevant alterations can rarely be observed in
unexpected tumor types. For instance, one patient with cervical cancer harbored a somatic
BRAFK601E mutation (Fig. 5e). While not previously reported in this tumor type, such a
patient may warrant consideration for therapies that target these alterations37. This
descriptive example highlights the potential benefit for comprehensive profiling in clinical
settings, although prospective implementation of this approach is needed to determine the
general applicability to clinical oncology.
Next, by combining mutation data from 12 tumor types, we observed a “tail” of low-
frequency alterations in clinically relevant cancer genes that warrant clinical investigation
but would not be apparent with smaller, single-tumor cohorts. This is demonstrated by a
series of observations involving genes in the phosphatidylinositide 3-kinase/mTOR
signaling pathway. In PIK3CA, both hotspot alterations and those requiring preclinical and
clinical evaluation were observed in 604 patients (Fig. 5f). Somatic mutations in TSC1,
which have been implicated in everolimus sensitivity in urothelial carcinomas38, 39, were
noted in 41 patients with a diverse array of tumor types (Fig. 5g). Somatic alterations in
MTOR itself, which may predict response and/or resistance to rapamycin analogs or mTOR
catalytic domain inhibitors40, were observed in 124 patients (Fig. 5h).
Finally, comprehensive profiling may also be useful for identifying patients who may be
intrinsically resistant to certain therapies. For instance, 21 therapy-naïve patients harbored
MEK1 somatic mutations (Fig. 5i); a subset of these mutations may predict resistance to
RAF and/or MEK inhibitors in specific clinical contexts41, 42. Critically, RAF and MEK
inhibitors are currently being studied in numerous cancer types, so prospective knowledge of
MEK1 status may impact treatment selection for patients with MEK1 mutations. Broadly,
these results demonstrate how global surveys of mutational patterns in clinically relevant
genes may impact clinical trial design and treatment selection.
Discussion
In contrast to previous studies driven by a single cancer type or data type, we systematically
evaluated patient survival prediction from different molecular data types and described the
potential prognostic and/or therapeutic relevance revealed across multiple cancer types,
raising several important issues related to the potential clinical utility of large-scale
molecular data.
Currently, only a few gene expression–based molecular prognostic markers have been
established in clinical practice. For the cancers surveyed here, none of the previously
reported gene expression signatures are routinely used in current clinical practice in lung and
kidney cancer. For GBM, although the status of a few molecular markers (e.g., MGMT
promoter methylation) is frequently ordered for patients, that finding exerts limited
influence on clinical decision making43. For OV, CA125 is the only marker accepted for
clinical use44. Our systematic assessment helped address one key issue related to the lack of
prognostic markers with clinical utility: statistical significance vs. magnitude difference.
Across the four TCGA patient cohorts, clinical variables appeared to be the most
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tinformative resources (C-index: 0.624–0.754); and molecular data alone often (9 out of 18
cases) had statistically significant predictive power above a random guess (C-index: 0.544–
0.718). Given the clinical-variable-only models, incorporating molecular data statistically
boosts the model performance (5 out of 18 cases) in three cancer types, including mRNA,
miRNA and protein expression, especially their molecular subtype information. However,
the absolute magnitude gains were very limited (Somers’ D, 2.2~22.9%; a 2.2% gain in
Somers’ D corresponds to a 2.2% increase of rank correlation coefficient between the
predicted risk score and the actual survival of the patients), suggesting that the information
content of clinical variables and molecular data are largely redundant in terms of patient
survival stratification. This echoes the observation that the number of cancer prognostic
molecular markers in clinical use is pitifully small, despite decades of protracted and
tremendous efforts45, 46. Currently, many investigators conclude the utility of their markers
of interest by heavily relying on P-value rather than the size of the difference in patient
outcomes47. Our study calls attention to the criteria of magnitude difference that should be
emphasized in future publications of tumor prognostic markers.
Another important related issue is reliability and reproducibility. The literature of tumor
biomarkers is plagued by publication bias and selective/incomplete reporting46, which
especially poses an acute challenge in the post-genomic era. In this regard, we have
developed an open-access model assessment platform for TCGA pan-cancer survival
prediction, which will (i) reduce the barrier to analyzing TCGA data by providing access to
well curated, computable datasets used as inputs to all models in our study; (ii) increase the
transparency and reproducibility of prognostic models by providing our models as re-
runnable source code and providing this capability to other researchers; and (iii) improve the
objectivity and rigor of future model assessments by providing a baseline set of model
scores based on pre-defined criteria and evaluation scores posted on a real-time, publically
available “leaderboard”. Such an effort not only helps improve prognostic models though a
community-based challenge48, 49, but also ensures transparency and reproducibility for
tumor biomarker identification. We expect to seed such a community effort to release the
whole dataset, prognostic models and evaluation criteria for future studies of clinically
usable prognostic models.
By exploring the spectrum of clinically actionable somatic alterations among 12 tumor
types, we identified multiple instances where alterations in clinically relevant genes were
observed in enough patients to rationalize clinical trial development across tumor types. This
was true even if these alterations were rarely observed in any single tumor type, leading to
so-called “bucket” trials. We also revealed how the potential applications of precision
oncology can be expanded to numerous additional patients with more extensive forms of
profiling. As the number of identified clinically actionable cancer genes and alterations
continues to rise8, prospective genomic profiling may inform individualized treatment plans
for patients with metastatic or localized disease, as these patients are guided toward
genomically-driven clinical trials. Importantly, many of the alterations observed in clinically
actionable cancer genes have either no known functional effect that may be consistent with a
clinical action or even have the converse effect. Through our cross-tumor analysis, we
expect that many of these alterations will emerge in preclinical and clinical studies, thereby
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tinforming their relative impact in specific clinical settings from a predictive/prognostic
standpoint when linked to relevant clinical outcomes.
Although our study provides important insights into the translation of biological data into
clinical utility, it has some limitations. First, we employed purely data-mining approaches to
prognostic modeling. Such a practice comes with a cost: we may miss some informative
individual features that could be identified by a candidate gene approach driven by prior
knowledge. Second, we did not analyze somatic mutations for prognostic utility because the
mutation data are binary and sparse across the patient cohorts. New methods should be
developed for assessing the prognostic power of large-scale mutation data. Third, effectively
combining multiple types of molecular data remains a technical challenge owing to the over-
fitting issue and widespread co-linearity of large-scale biological data. Therefore, one
important future direction is to build prognostic models that incorporate clinical variables
and multiple types of molecular data, which may provide crucial complementary
information. In that regard, more effective feature selection strategies should be developed.
Finally, because TCGA patient samples were collected from multiple source sites for the
purpose of comprehensive molecular profiling and were characterized at different centers,
this practice may introduce both heterogeneity and bias. In addition, the resulting clinical
annotation of patient samples may not be as rigorous and complete as those obtained from
clinical trials. Therefore, further efforts, especially independent validations with clinical
trial-grade follow-up, are crucial for assessing our findings from TCGA data.
Online Methods
Core dataset compilation
We downloaded overall survival data and SCNA data from Firehose (https://
confluence.broadinstitute.org/display/GDAC/Home). We obtained the clinical variables
from TCGA Data Portal (https://tcga-data.nci.nih.gov/tcga/) and the molecular data
(including DNA methylation, mRNA, miRNA and protein expression) from the Pan-cancer
project (syn300013) on Synapse (http://www.synapse.org). Specifically, molecular data
from the following platforms were used in our study. For SCNA, the platform is Affymetrix
Genome-Wide Human SNP Array 6.0 (arm-level and focal-level copy number calls were
derived from Firehose: https://confluence.broadinstitute.org/display/GDAC/Home). For
DNA methylation, the platform is Illumina Infinium Human DNA Methylation 27K (for
GBM and OV) or 450K (for KIRC and LUSC, we retained only the probes that most
negatively correlated with gene expression according to Firehose). For mRNA expression,
the platform was either Agilent 244K Custom Gene Expression G4502A (for GBM and OV)
or Illumina HiSeq 2000 RNA Sequencing V2 (for KIRC and LUSC). For miRNA
expression, the platform was either Agilent 8×15K Human miRNA-specific microarray
platform (for GBM and OV) or Illumina Genome Analyzer/HiSeq 2000 miRNA sequencing
platform (for KIRC and LUSC). For protein expression, the platform was the MD Anderson
Reverse Phase Protein Array (RPPA) Core platform and both total protein and
phosphorylated protein were included in this study as distinct molecular features. For each
cancer type, we defined the sample intersection across all the platforms as the core sample
set. We included neither DNA methylation data in the LUSC core, nor protein expression
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tdata in the GBM core in order to preserve a statistically sufficient sample size. For each
molecular data type, in additional to gene-level features, we included the NMF subtypes
from Firehose analyses reported on January 16, 2013. All core clinical and genomic/
proteomic data used to construct survival models, as well as the training and test dataset
splits, are available at the Synapse homepage of our project (accession number syn1710282,
doi:10.7303/syn1710282). The full Pan-Cancer dataset is available at the Synapse Pan-
Cancer home page (accession number syn300013, doi:10.7303/syn300013).
Model training and performance comparison
For each core set, we randomly split the samples into two groups: 80% as the training set
and 20% as the test set. On the training set, we first performed a pre-selection step to keep
the top significant features correlated with overall survival (univariate Cox model,
likelihood ratio test P < 0.05). To obtain better convergence of the training model, we
required that the retained feature number did not exceed the number of events (deaths) in the
training set. We used two computational methods to train the models: (i) Cox: the Cox
proportional hazards model with LASSO for feature selection, and (ii) RSF: random survival
forest. The univariate and multivariate Cox models were built with the R package
“survival”; the LASSO was performed using the R package “glmnet” and the penalty
parameter λ was chosen based on the 5-fold cross-validation within the training set; and the
RSF models were built using the R package “RandomSurvivalForest” with the
recommended default parameters. We then applied the models thereby obtained to the test
set for prediction, and calculated the C-index using the R package “survcomp”. For each
core set, the above procedure was repeated 100 times to generate 100 C-indexes. To
compare the performance across different data types, we first chose the better performing
method (Cox or RSF) and then used its results based on the Wilcoxon signed rank test to
calculate the P value (using 0.05 as the significance cutoff).
To assess the predictive power of integrating molecular data with clinical variables, we
slightly modified the Cox method to include both clinical and molecular features. We used
the clinical features (such as patient age and gender, tumor stage and grade, and Karnofsky
performance score, upon availability) that were significantly correlated with survival
(likelihood ratio test P < 0.05 in both the univariate Cox model and the full model with all
clinical variables) as the baseline to build the clinical Cox model. We then combined the
gene-level features that better fit the existing model (through performing a feature selection
step against the residuals) or the subtype features with the clinical variables to build a new
multivariate Cox model. We performed the RSF method as before.
To evaluate the effect of feature selection, for the data exhibiting striking discrepancies (i.e.,
clinical + molecular data for GBM and LUSC), we applied different feature selection
methods before RSF: i) the same LASSO approach as for Cox; ii) minimal depth variable
selection; and iii) variable hunting. We calculated the C-indexes when applying these new
models to the same test sets. To evaluate the effect of sample size, for the molecular models
with substantial predictive power (median C-index > 0.6), we conducted a serial sampling of
various portions (ranging from 0.2–1, with a increment of 0.1) of the original training
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tsamples as the new training set, from which we built the models using the same approach
and calculated the C-index when applying these models to the same test set.
Building multiclass classifier from known NMF subtypes
Using the TCGA OV miRNA expression data as the explanatory variables and the three-
class NMF subtypes derived from these expression data by Firehose as the response
variable, we built the multiclass classifier (multinomial logistic regression model) using a
scheme adapted from Yuan et al50. We first cleaned out the expression data by retaining the
common features between TCGA data and the independent dataset and performed sample-
wise centering. We then built the multiclass classifier from the TCGA data and evaluated its
performance through 5-fold cross validation. During each of the five iterations, feature
selection by LASSO (class = “multinomial”) and tuning of the penalty parameter λ were
based on 80% of the data, and the prediction (using the R package “glmnet”) was made to
the remaining 20% of the data, where class labels was assigned according to the class with
the largest probability. The predictions from the five iterations were combined and the
AUCs were calculated by the R package “ROCR”. Finally, we trained the classifier using
the whole TCGA data and applied it to the independent OV dataset for the final prediction.
Analysis of important biological features in the top prognostic models
The Kaplan-Meier survival curves were drawn according to the samples’ original NMF
subtypes or predicted classes, and the log-rank test P-values were calculated using the R
package “survival”. The association of individual features with survival (better or worse)
was decided based on the hazard ratio (HR) from the univariate Cox model, where an HR
greater than 1 represented a worse prognosis. Wald’s test P-values were used to assess the
significance. For expression values obtained through sequencing (i.e., KIRC miRNA
expression), the raw values were log2 transformed before the univariate Cox analysis. The
enriched gene pathways were identified through IPA (Ingenuity Systems®,
www.ingenuity.com).
Cross–tumor-type survival prediction
For the cancers that shared the same platforms for the same type of genomic data (e.g.,
microarray for GBM and OV mRNA expression, RNA-seq for KIRC and LUSC mRNA
expression), we first obtained the common features shared by any two cancers in a pairwise
manner. Then we trained the Cox model from the shared molecular features of one cancer
and applied the model trained to the same 100 test sample sets utilized in the global analysis
of the other cancer. C-indexes were calculated accordingly. To test the effect of sample size,
for the OV-KIRC case, we randomly sampled the same number of OV samples as the KIRC
training size and repeated the whole analysis. We used the Wilcoxon signed rank test to
compare the performance of the model trained with data from different cancers. We further
confirmed this result using an independent approach and an independent sample partition
(Supplementary Fig. 11). The sample partition was done using standard 5-fold cross-
validation on the KIRC data. For each fold, we trained non-parametric unregularized Cox
proportional hazards models using the glmnet package in R. We repeated the cross-
validation process 30 times, randomly choosing a 5-fold split each time. Finally, the KIRC
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tpatients were stratified using the SCNA signatures derived from OV, and the Kaplan-Meier
curves were drawn based on the median risk score.
Dichotomization of survival data
For each cancer type, we dichotomized the censored continuous survival data by assigning a
cutoff time (survival milestone) of 1 year for individuals with GBM, 2 years for LUSC, 3
years for OV and 4 years for KIRC. The individuals who lived beyond the cutoff time were
labeled as 1; the deceased were labeled as 0. The individuals with survival times that were
censored before the cutoff were excluded. The different cutoffs were chosen in order to
reach a balance between the event ratio and the sample size. The dichotomized survival data
were deposited in Synapse (syn1748545).
Classification algorithms for dichotomized survival data
For each dichotomized survival dataset, we used two pre-selection strategies (ANOVA and
shrinking centroids) and 8 classification algorithms: diagonal discriminant analysis (DDA),
K-nearest neighbor (KNN), discriminant analysis (DA), logistic regression (LR), nearest
centroid (NC), partial least square (PLS), random forest (RF) and support vector machine
(SVM). The performance was assessed in 10-fold cross-validation, and AUCs were
calculated as the measurement. For KNN, we varied the number of candidate neighbors
from 1 to 9 (odd numbers only) and used the Euclidean distance as the measure of distance.
For NC, we assigned equal prior probabilities. For DDA, DA, and PLS, we chose the linear
discriminant function with equal prior probabilities. For SVM, we chose the radial basis
kernel. The parameter C (the cost) ranged from 1 to 1001, in increments of 100, and gamma
ranged from 10−10 to 10−2, moving one decimal place per time. For RF, 1000 trees were
used. The other parameters were chosen by default. The number of features after pre-
selection ranged from 10 to 50, in increments of 10.
Variability analysis for modeling factors
There are five factors that can potentially affect the performance of binary classification:
cancer type, data type (clinical or individual molecular features), pre-selection strategies, the
number of features after pre-selection and classification algorithms. We used ANOVA to
assess the variability contributed by these factors and their interactions, and the Akaike
information criterion in stepwise model selection for significant factors and interactions. The
estimated variance components were then divided by their total in order to compare the
proportion of variability explained by each modeling factor. To remove the effect of sample
size, we performed a size-adjusted analysis, in which we kept the sample size consistent
across all cancer types by randomly sampling 77 samples according to the smallest sample
(which was LUSC) from KIRC, GBM and OV, and repeated the same procedure for the
original dichotomized sets.
Identification of somatic alterations in clinically relevant genes
Somatic mutations and indels called from exome sequencing of matched tumor and normal
genome pairs from 12 TCGA projects were aggregated using mutation annotation format
(MAF) files from Synapse (syn1710680). Each alteration was ranked for clinical relevance
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tusing a heuristic algorithm34, 35. Clinical actionability was defined at the gene level: any
gene that, when somatically altered in cancer, predicted response or resistance to a specific
therapy, had diagnostic potential, or had prognostic significance, was considered a clinically
actionable gene. These genes were derived by a review of the primary literature,
consultation with experts, and manual curation. A complete list is available at
www.broadinstitute.org/cancer/cga/target. For the purpose of understanding the distribution
of hotspot alterations in BRAF and PIK3CA, the following definitions were assigned:
hotspot alterations in BRAF were defined as those leading to V600E, V600K, and V600R
protein changes. Similarly, hotspot alterations in PIK3CA were restricted to those that
resulted in E545K and H1047R protein changes. All code for this effort was generated using
the R statistical package.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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tFigure 1. Comparison of the survival predictive power of clinical variables, molecular data and
their combinations
(a) An overview of the computational approach. (b)–(e) C-indexes by models trained from
clinical variables, individual molecular data alone or in combination with clinical variables
in (b) KIRC (Ntotal = 243), (c) OV(Ntotal = 379), (d) GBM (Ntotal = 210) and (e) LUSC
(Ntotal = 121). For each cancer type, during each of the 100 times of random splitting, 80%
of the total samples were used to train the model and the remaining 20% as the test set for C-
index calculations. The blue box highlights the model built from individual molecular data
that shows comparable performance to that based on clinical variables (two-sided Wilcoxon
signed rank test, P > 0.05); and the magenta boxes highlight the models integrating
molecular data and clinical variables that show better performance than that based on only
clinical variables (two-sided Wilcoxon signed rank test, FDR < 0.01).
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tFigure 2. Biological insights from the top prognostic models
(a) Consensus nonnegative matrix factorization (NMF) clustering of the TCGA OV miRNA
expression data reveals three molecular subtypes (clusters). (b) The ROC curves of the
multiclass classifier against NMF subtypes trained from the TCGA OV miRNA expression
data through five-fold cross-validation. (c) The Kaplan-Meier plot of the patients from the
TCGA OV core set stratified by OV miRNA-expression NMF subtypes. (d) The Kaplan-
Meier plot of the patients from the independent OV cohort stratified by predicted miRNA
NMF subtypes using the classifier in (b). (e) The Kaplan-Meier plot of the patients from the
LUSC core set stratified by LUSC protein-expression NMF subtypes. (f) The top
differentially expressed protein markers among LUSC protein-expression NMF subtypes
grouped by pathways/functions. (g) The miRNAs selected by LASSO for the KIRC clinical
+ miRNA integrative model.
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tFigure 3. Models trained from OV SCNA data can predict survival of individuals with KIRC
(a) From left to right: C-index for the models trained from KIRC SCNA data (Ntraining=
192), C-index for the models trained from SCNA of OV sample sets with the same size as
the KIRC training sets (Ntraining = 192), and C-index for the model trained from SCNA of
the whole OV core set (Ntraining = 379). The OV model trained from the whole OV core set
showed higher predictive power than the model trained from SCNA data of independent
KIRC training samples (two-sided Wilcoxon signed rank test, P = 4.7 × 10−9). (b) The bar
plot of amplification Q-value of arm-level SCNA features from GISTIC2. The features
included in the model trained from OV SCNA data are shown in red. The KIRC q-values of
the features selected from OV SCNA data were lower than those not selected (two-sided
Wilcoxon rank sum test, P = 1.6 × 10−3).
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tFigure 4. Predictive performance of clinical variables, molecular data and their combination on
dichotomized survival data
The best AUC achieved by each classification algorithm for each clinical/molecular/
combination dataset in (a) KIRC (Ntotal = 150), (b) GBM (Ntotal = 155), (c) OV (Ntotal =
252) and (d) LUSC (Ntotal = 77). (e) Variation explained by modeling factors and their
interactions. Abbreviations for classification algorithms: diagonal discriminant analysis
(DDA), K-nearest neighbor (KNN), discriminant analysis (DA), logistic regression (LR),
nearest centroid (NC), partial least square (PLS), random forest (RF) and support vector
machine (SVM). AUCs were calculated based on 10-fold cross-validation.
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tFigure 5. Alterations in clinically relevant genes across 12 tumor types
(a)–(b) Examination of mutations and indels in 3,277 patients representing 12 tumor types
reveals a long tail of the frequency distribution of alterations in clinically relevant genes that
warrant further exploration across 12 tumor types. Expanding tumor profiling beyond
hotspot profiling technologies (c) to whole exome sequencing (d) increases the percentage
of patients in all tumor types that may harbor clinically relevant alterations. (e) Hotspot
alterations in known cancer genes occur at low frequencies in unexpected tumor types. (f)–
(i) Alterations in emerging genes with potential clinical relevance are observed across tumor
types. For a key to the tumor types, see Supplementary Table 4.
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